Results 111 to 120 of about 342 (145)
Phase 3 Trial of Nemolizumab in Patients With Prurigo Nodularis [PDF]
New England Journal of Medicine, 2023 BACKGROUND Prurigo nodularis is a chronic, debilitating, and severely pruritic neuroimmunologic skin disease. Nemolizumab, an interleukin-31 receptor alpha antagonist, down-regulates key pathways in the pathogenesis of prurigo nodularis. METHODS In this phase 3, double-blind, multicenter, randomized trial, we assigned adults with moderate-to-severe ...
Sébastien Barbarot, Paul Carle
exaly +10 more sources
Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis
New England Journal of Medicine, 2020 Prurigo nodularis is a chronic pruritic skin disease with multiple nodular skin lesions. Nemolizumab is a monoclonal antibody targeting the interleukin-31 receptor, which is involved in the pathogenesis of prurigo nodularis.We conducted a 12-week, randomized, double-blind, phase 2 trial of nemolizumab (at a dose of 0.5 mg per kilogram of body weight ...
Jean-Philippe Lacour, Laurent Misery
exaly +4 more sources
A Critical Evaluation of Nemolizumab for Prurigo Nodularis
Expert Review of Clinical ImmunologyPrurigo nodularis (PN) is a chronic inflammatory skin condition that presents with intensely pruritic, hyperkeratotic nodules. The pathophysiology underlying PN is not entirely clear, making treatment challenging. Patients often require a multimodal approach, although many of the available therapies have low efficacy or adverse effects.In this review ...
exaly +4 more sources
Nemolizumab in Prurigo Nodularis Up to 100 Weeks: OLYMPIA LTE Interim Analysis
Journal of the European Academy of Dermatology and VenereologyIn this interim analysis of the OLYMPIA long‐term extension trial, nemolizumab exhibited sustained efficacy and was well tolerated through 100 weeks, with most adverse events being mild/moderate. Patients showed clinically meaningful improvements in core signs and symptoms.
Laurent Misery +2 more
exaly +3 more sources
Nemolizumab in Patients With Moderate-to-Severe Atopic Dermatitis: Randomized, Phase II, Long-Term Extension Study [PDF]
Journal of Allergy and Clinical Immunology, 2018 Background: Nemolizumab, an anti–IL-31 receptor A mAb, improved pruritus, dermatitis, and sleep in adults with moderate-to-severe atopic dermatitis that was inadequately controlled by topical treatments in a phase II, 12-week, randomized, double-blind ...
Kenji Kabashima +2 more
exaly +2 more sources
Trial of Nemolizumab and Topical Agents for Atopic Dermatitis With Pruritus
New England Journal of Medicine, 2020 Nemolizumab is a subcutaneously administered humanized monoclonal antibody against interleukin-31 receptor A, which is involved in pruritus and inflammation in atopic dermatitis. In phase 2 studies, nemolizumab lessened the severity of atopic dermatitis.In a 16-week, double-blind, phase 3 trial, we randomly assigned Japanese patients with atopic ...
Hiroshi Komazaki +2 more
exaly +3 more sources
Journal of DermatologyNemolizumab, an anti\u2010interleukin\u201031 receptor A monoclonal antibody, has been approved in Japan for treating atopic dermatitis (AD)\u2010associated pruritus.
Ken Igawa +2 more
exaly +2 more sources
Nemolizumab in Moderate to Severe Atopic Dermatitis: An Exploratory Analysis of Work Productivity and Activity Impairment in a Randomized Phase II Study [PDF]
Journal of Dermatology, 2019 Atopic dermatitis negatively impacts work productivity. This study investigated the impact of nemolizumab on work productivity and activity impairment in adults with moderate to severe atopic dermatitis inadequately controlled by topical treatments in a ...
Kenji Kabashima +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Selection of Nemolizumab Clinical Dosage for Atopic Dermatitis
Journal of Drugs in Dermatology, 2023Nemolizumab is a monoclonal antibody directed against the interleukin-31 receptor A subunit, which is involved in the pathogenesis of pruritus and inflammation in atopic dermatitis (AD). Clinical trial results were combined with population PK (popPK) and pharmacokinetic/ pharmacodynamic (PK/PD) models to optimize nemolizumab dosing.
Nathalie, Wagner +11 more
openaire +2 more sources